Sana Biotechnology/$SANA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Ticker
$SANA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
194
ISIN
US7995661045
Website
SANA Metrics
BasicAdvanced
$916M
-
-$0.88
1.79
-
Price and volume
Market cap
$916M
Beta
1.79
52-week high
$7.40
52-week low
$1.26
Average daily volume
5.5M
Financial strength
Current ratio
3.4
Quick ratio
3.158
Long term debt to equity
37.455
Total debt to equity
43.674
Profitability
EBITDA (TTM)
-199.493
Management effectiveness
Return on assets (TTM)
-23.84%
Return on equity (TTM)
-71.44%
Valuation
Price to book
4.38
Price to tangible book (TTM)
98.89
Price to free cash flow (TTM)
-4.279
Free cash flow yield (TTM)
-23.37%
Free cash flow per share (TTM)
-94.89%
Growth
Earnings per share change (TTM)
-42.39%
3-year earnings per share growth (CAGR)
-7.82%
What the Analysts think about SANA
Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
Bulls say / Bears say
Sana Biotechnology's hypoimmune (HIP) platform has demonstrated promising results in type 1 diabetes (T1D) treatments, with six-month clinical data showing that transplanted pancreatic islet cells function without immunosuppression, potentially revolutionizing T1D therapy. (Sana Biotechnology News Releases)
The company's diverse pipeline, including programs like SC291 for autoimmune diseases and SG299 for in-vivo CAR-T therapies, positions it to address multiple high-need therapeutic areas, enhancing its growth potential. (Investing.com)
Analysts maintain a bullish outlook on Sana, with a consensus price target of $9.33, suggesting significant upside from the current trading price. (Simply Wall St)
Sana reported no revenues in Q1 2025, reflecting its early-stage status and the financial risks associated with pre-revenue biotech companies. (Investing.com)
The company faces intense competition in the autoimmune disease space, with numerous CAR-T and T-cell engager therapies in development, potentially hindering market penetration. (Investing.com)
Sana's stock exhibits high volatility, with a beta of 1.86, indicating greater risk compared to the broader market, which may deter risk-averse investors. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
SANA Financial Performance
Revenues and expenses
SANA Earnings Performance
Company profitability
SANA News
AllArticlesVideos
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
GlobeNewsWire·3 weeks ago
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
GlobeNewsWire·1 month ago
Sana Biotechnology to Present at June 2025 Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sana Biotechnology stock?
Sana Biotechnology (SANA) has a market cap of $916M as of July 11, 2025.
What is the P/E ratio for Sana Biotechnology stock?
The price to earnings (P/E) ratio for Sana Biotechnology (SANA) stock is 0 as of July 11, 2025.
Does Sana Biotechnology stock pay dividends?
No, Sana Biotechnology (SANA) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Sana Biotechnology dividend payment date?
Sana Biotechnology (SANA) stock does not pay dividends to its shareholders.
What is the beta indicator for Sana Biotechnology?
Sana Biotechnology (SANA) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.